Information Provided By:
Fly News Breaks for March 18, 2019
MDT, EW
Mar 18, 2019 | 08:57 EDT
Wells Fargo analyst Lawrence Biegelsen raised his price target for Edwards Lifesciences to $202 from $188 after the results of the company's low-risk TAVR trial was presented at the 2019 American College of Cardiology meeting. The analyst sees potential upside to his forecast given the strong low-risk results presented at ACC. Biegelsen reiterates an Outperform rating on the shares.